Evidence map›Paper›PMID 34593938›Full record

ArticleScientific reports2021

Associations of vascular and bone status in arthritis patients.

Anita Pusztai, Attila Hamar, Monika Czókolyová, Katalin Gulyás, Ágnes Horváth, Edit Végh, Zsófia Pethő, Szilvia Szamosi, Emese Balogh, Nóra Bodnár and 13 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Postmenopausal Osteoporosis, Endothelial Dysfunction, and Cardiovascular Risk.Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases · 2026
    Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 1 institution in 3 countries.

Anita PusztaiDivision of Rheumatology, Faculty of Medicine, University of Debrecen, Nagyerdei Str 98, Debrecen, 4032, Hungary.
Attila HamarDivision of Rheumatology, Faculty of Medicine, University of Debrecen, Nagyerdei Str 98, Debrecen, 4032, Hungary.
Monika CzókolyováDivision of Rheumatology, Faculty of Medicine, University of Debrecen, Nagyerdei Str 98, Debrecen, 4032, Hungary.
Katalin GulyásDivision of Rheumatology, Faculty of Medicine, University of Debrecen, Nagyerdei Str 98, Debrecen, 4032, Hungary.
Ágnes HorváthDivision of Rheumatology, Faculty of Medicine, University of Debrecen, Nagyerdei Str 98, Debrecen, 4032, Hungary.
Edit VéghDivision of Rheumatology, Faculty of Medicine, University of Debrecen, Nagyerdei Str 98, Debrecen, 4032, Hungary.
Zsófia PethőDivision of Rheumatology, Faculty of Medicine, University of Debrecen, Nagyerdei Str 98, Debrecen, 4032, Hungary.
Szilvia SzamosiDivision of Rheumatology, Faculty of Medicine, University of Debrecen, Nagyerdei Str 98, Debrecen, 4032, Hungary.
Emese BaloghDivision of Rheumatology, Faculty of Medicine, University of Debrecen, Nagyerdei Str 98, Debrecen, 4032, Hungary.
Nóra BodnárDivision of Rheumatology, Faculty of Medicine, University of Debrecen, Nagyerdei Str 98, Debrecen, 4032, Hungary.
Levente BodokiDivision of Rheumatology, Faculty of Medicine, University of Debrecen, Nagyerdei Str 98, Debrecen, 4032, Hungary.
Ágnes SzentpéteryDivision of Rheumatology, Faculty of Medicine, University of Debrecen, Nagyerdei Str 98, Debrecen, 4032, Hungary.
Harjit Pal BhattoaDepartment of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
György KerekesDepartment of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Balázs JuhászDepartment of Oncology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Éva SzekaneczDepartment of Oncology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Katalin HodosiDivision of Rheumatology, Faculty of Medicine, University of Debrecen, Nagyerdei Str 98, Debrecen, 4032, Hungary.
Andrea DomjánDivision of Rheumatology, Faculty of Medicine, University of Debrecen, Nagyerdei Str 98, Debrecen, 4032, Hungary.
Sándor SzántóDivision of Rheumatology, Faculty of Medicine, University of Debrecen, Nagyerdei Str 98, Debrecen, 4032, Hungary.
Hennie G RatermanDepartment of Rheumatology, Northwest Clinics, Alkmaar, The Netherlands.
Willem F LemsAmsterdam Rheumatology and Immunology Centre, Amsterdam, The Netherlands.
Zoltán SzekaneczDivision of Rheumatology, Faculty of Medicine, University of Debrecen, Nagyerdei Str 98, Debrecen, 4032, Hungary. szekanecz.zoltan@med.unideb.hu.
Gabriella SzűcsDivision of Rheumatology, Faculty of Medicine, University of Debrecen, Nagyerdei Str 98, Debrecen, 4032, Hungary.
University of Debrecen · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiovascular (CV) disease and osteoporosis (OP) have been associated with rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Bone and vascular biomarkers and parameters along with the effect of 1-year anti-TNF therapy on these markers were assessed in order to determine correlations between vascular pathophysiology and bone metabolism in RA and AS. Thirty-six patients treated with etanercept or certolizumab pegol and 17 AS patients treated with ETN were included in a 12-month follow-up study. Bone and vascular markers were previously assessed by ELISA. Bone density was measured by DXA and quantitative CT (QCT). Flow-mediated vasodilation (FMD), common carotid intima-media thickness (IMT) and pulse-wave velocity (PWV) were assessed by ultrasound. Multiple correlation analyses indicated associations between bone and vascular markers. Osteoprotegerin, sclerostin and cathepsin K were significantly associated with FMD, IMT and PWV, respectively (p < 0.05). Moreover, total and trabecular BMD determined by QCT inversely correlated with IMT (p < 0.05). On the other hand, among vascular parameters, platelet-derived growth factor BB and IMT correlated with DXA femoral and QCT total BMD, respectively (p < 0.05). In the RM-ANOVA analysis, anti-TNF treatment together with baseline osteocalcin, procollagen 1 N-terminal propeptide (P1NP) or vitamin D3 levels determined one-year changes in IMT (p < 0.05). In the MANOVA analysis, baseline disease activity indices (DAS28, BASDAI), the one-year changes in these indices, as well as CRP exerted effects on multiple correlations between bone and vascular markers (p < 0.05). As the pattern of interactions between bone and vascular biomarkers differed between baseline and after 12 months, anti-TNF therapy influenced these associations. We found a great number of correlations in our RA and AS patients undergoing anti-TNF therapy. Some of the bone markers have been associated with vascular pathophysiology, while some vascular markers correlated with bone status. In arthritis, systemic inflammation and disease activity may drive both vascular and bone disease.

Indexed as

Disease SusceptibilityAdultAgedAged, 80 and overArthritisBiomarkersBone DensityBone DiseasesFemaleHumansMaleMiddle AgedPrognosisSymptom AssessmentUltrasonographyVascular DiseasesBiomarkers

Identifiers

PMID34593938
PMCPMC8484288
OpenAlexW3204165729

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.